Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (inlfiximab) and Herceptin (trastuzumab).

B.J.M. Peters; M.A. Capelle; T. Arvinte; E.M.W van de Garde

Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (inlfiximab) and Herceptin (trastuzumab).

B.J.M. Peters, M.A. Capelle, T. Arvinte, E.M.W van de Garde

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	162-170
Number of pages	9
Journal	mAbs
Volume	5
Issue number	1
Publication status	Published - 2013

Cite this

@article{b020f5ec559f4937924c0c6b86f9a843,

title = "Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (inlfiximab) and Herceptin (trastuzumab).",

author = "B.J.M. Peters and M.A. Capelle and T. Arvinte and {van de Garde}, E.M.W",

year = "2013",

language = "Undefined/Unknown",

volume = "5",

pages = "162--170",

journal = "mAbs",

issn = "1942-0862",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (inlfiximab) and Herceptin (trastuzumab).

AU - Peters, B.J.M.

AU - Capelle, M.A.

AU - Arvinte, T.

AU - van de Garde, E.M.W

PY - 2013

Y1 - 2013

M3 - Article

SN - 1942-0862

VL - 5

SP - 162

EP - 170

JO - mAbs

JF - mAbs

IS - 1

ER -